Live feed08:00:00·23hPRReleasevia QuantisnowMadrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH PipelineByQuantisnow·Wall Street's wire, on your screen.MDGL· Madrigal Pharmaceuticals Inc.Health Care
